2016 Q3 Form 10-Q Financial Statement
#000114420417059071 Filed on November 14, 2017
Income Statement
| Concept | 2016 Q3 |
|---|---|
| Revenue | $0.00 |
| YoY Change | |
| Cost Of Revenue | |
| YoY Change | |
| Gross Profit | |
| YoY Change | |
| Gross Profit Margin | |
| Selling, General & Admin | $1.270M |
| YoY Change | 0.0% |
| % of Gross Profit | |
| Research & Development | $2.486M |
| YoY Change | 26.19% |
| % of Gross Profit | |
| Depreciation & Amortization | $268.4K |
| YoY Change | 281.66% |
| % of Gross Profit | |
| Operating Expenses | $2.486M |
| YoY Change | -24.66% |
| Operating Profit | |
| YoY Change | |
| Interest Expense | $10.00K |
| YoY Change | 519.96% |
| % of Operating Profit | |
| Other Income/Expense, Net | |
| YoY Change | |
| Pretax Income | -$3.820M |
| YoY Change | 16.11% |
| Income Tax | |
| % Of Pretax Income | |
| Net Earnings | -$3.820M |
| YoY Change | 16.18% |
| Net Earnings / Revenue | |
| Basic Earnings Per Share | |
| Diluted Earnings Per Share | -$5.380M |
| COMMON SHARES | |
| Basic Shares Outstanding | 35.53M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q3 |
|---|---|
| SHORT-TERM ASSETS | |
| Cash & Short-Term Investments | $3.370M |
| YoY Change | 43.4% |
| Cash & Equivalents | $3.370M |
| Short-Term Investments | |
| Other Short-Term Assets | $360.0K |
| YoY Change | -29.41% |
| Inventory | |
| Prepaid Expenses | |
| Receivables | |
| Other Receivables | |
| Total Short-Term Assets | $3.730M |
| YoY Change | 22.11% |
| LONG-TERM ASSETS | |
| Property, Plant & Equipment | $5.900M |
| YoY Change | 7.35% |
| Goodwill | |
| YoY Change | |
| Intangibles | |
| YoY Change | |
| Long-Term Investments | |
| YoY Change | |
| Other Assets | $380.0K |
| YoY Change | -32.14% |
| Total Long-Term Assets | $6.330M |
| YoY Change | 3.5% |
| TOTAL ASSETS | |
| Total Short-Term Assets | $3.730M |
| Total Long-Term Assets | $6.330M |
| Total Assets | $10.06M |
| YoY Change | 9.71% |
| SHORT-TERM LIABILITIES | |
| YoY Change | |
| Accounts Payable | $1.290M |
| YoY Change | -22.75% |
| Accrued Expenses | $20.00K |
| YoY Change | 100.0% |
| Deferred Revenue | |
| YoY Change | |
| Short-Term Debt | $60.00K |
| YoY Change | 0.0% |
| Long-Term Debt Due | $0.00 |
| YoY Change | -100.0% |
| Total Short-Term Liabilities | $1.490M |
| YoY Change | -23.98% |
| LONG-TERM LIABILITIES | |
| Long-Term Debt | $0.00 |
| YoY Change | |
| Other Long-Term Liabilities | $370.0K |
| YoY Change | -17.78% |
| Total Long-Term Liabilities | $370.0K |
| YoY Change | -18.43% |
| TOTAL LIABILITIES | |
| Total Short-Term Liabilities | $1.490M |
| Total Long-Term Liabilities | $370.0K |
| Total Liabilities | $1.850M |
| YoY Change | -23.24% |
| SHAREHOLDERS EQUITY | |
| Retained Earnings | |
| YoY Change | |
| Common Stock | |
| YoY Change | |
| Preferred Stock | |
| YoY Change | |
| Treasury Stock (at cost) | |
| YoY Change | |
| Treasury Stock Shares | |
| Shareholders Equity | $8.200M |
| YoY Change | |
| Total Liabilities & Shareholders Equity | $10.06M |
| YoY Change | 9.71% |
Cashflow Statement
| Concept | 2016 Q3 |
|---|---|
| OPERATING ACTIVITIES | |
| Net Income | -$3.820M |
| YoY Change | 16.18% |
| Depreciation, Depletion And Amortization | $268.4K |
| YoY Change | 281.66% |
| Cash From Operating Activities | -$2.968M |
| YoY Change | 18.26% |
| INVESTING ACTIVITIES | |
| Capital Expenditures | -$130.0K |
| YoY Change | -77.59% |
| Acquisitions | |
| YoY Change | |
| Other Investing Activities | $70.00K |
| YoY Change | -63.16% |
| Cash From Investing Activities | -$61.02K |
| YoY Change | -84.35% |
| FINANCING ACTIVITIES | |
| Cash Dividend Paid | |
| YoY Change | |
| Common Stock Issuance & Retirement, Net | |
| YoY Change | |
| Debt Paid & Issued, Net | |
| YoY Change | |
| Cash From Financing Activities | $2.333M |
| YoY Change | -11765.3% |
| NET CHANGE | |
| Cash From Operating Activities | -$2.968M |
| Cash From Investing Activities | -$61.02K |
| Cash From Financing Activities | $2.333M |
| Net Change In Cash | -$696.3K |
| YoY Change | -76.16% |
| FREE CASH FLOW | |
| Cash From Operating Activities | -$2.968M |
| Capital Expenditures | -$130.0K |
| Free Cash Flow | -$2.838M |
| YoY Change | 47.06% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q3 | antb |
Compensation And Benefits For Research And Development
CompensationAndBenefitsForResearchAndDevelopment
|
1303840 | USD |
| CY2017Q3 | antb |
Compensation And Benefits For Research And Development
CompensationAndBenefitsForResearchAndDevelopment
|
1500864 | USD |
| CY2016Q3 | antb |
Consultants And Outside Costs
ConsultantsAndOutsideCosts
|
271475 | USD |
| CY2017Q3 | antb |
Consultants And Outside Costs
ConsultantsAndOutsideCosts
|
130361 | USD |
| CY2016Q3 | antb |
Investor Relations
InvestorRelations
|
68107 | USD |
| CY2017Q3 | antb |
Investor Relations
InvestorRelations
|
59871 | USD |
| CY2016Q3 | antb |
Compensation And Benefits For General And Administrative
CompensationAndBenefitsForGeneralAndAdministrative
|
866901 | USD |
| CY2017Q3 | antb |
Compensation And Benefits For General And Administrative
CompensationAndBenefitsForGeneralAndAdministrative
|
1795427 | USD |
| CY2016Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1823 | USD |
| CY2017Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1823 | USD |
| CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
268355 | USD |
| CY2017Q3 | us-gaap |
Depreciation
Depreciation
|
266613 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
889028 | USD |
| CY2017Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1507699 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2968310 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4905007 | USD |
| CY2016Q3 | us-gaap |
Cash Period Increase Decrease
CashPeriodIncreaseDecrease
|
-696273 | USD |
| CY2017Q3 | us-gaap |
Cash Period Increase Decrease
CashPeriodIncreaseDecrease
|
-470823 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2333060 | USD |
| CY2017Q3 | antb |
Facilities And Other Costs
FacilitiesAndOtherCosts
|
502657 | USD |
| CY2016Q3 | antb |
Facilities And Other Costs
FacilitiesAndOtherCosts
|
398907 | USD |
| CY2017Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4440000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-61023 | USD |
| CY2016Q3 | antb |
Warrant Expense
WarrantExpense
|
0 | USD |
| CY2017Q3 | antb |
Warrant Expense
WarrantExpense
|
14847 | USD |
| CY2016Q2 | us-gaap |
Cash
Cash
|
4062013 | USD |
| CY2016Q3 | us-gaap |
Cash
Cash
|
3365740 | USD |
| CY2016Q3 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
126956 | USD |
| CY2017Q3 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
5816 | USD |
| CY2017Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5816 | USD |
| CY2017Q3 | us-gaap |
Payments For Proceeds From Other Deposits
PaymentsForProceedsFromOtherDeposits
|
0 | USD |
| CY2016Q3 | us-gaap |
Payments For Proceeds From Other Deposits
PaymentsForProceedsFromOtherDeposits
|
-65933 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-273637 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-84636 | USD |
| CY2017Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
4500000 | USD |
| CY2016Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
2692399 | USD |
| CY2017Q3 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
60000 | USD |
| CY2016Q3 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
336211 | USD |
| CY2017Q3 | antb |
Increase Decrease In Deferred Lease Liability
IncreaseDecreaseInDeferredLeaseLiability
|
-24975 | USD |
| CY2016Q3 | antb |
Increase Decrease In Deferred Lease Liability
IncreaseDecreaseInDeferredLeaseLiability
|
-29462 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-92845 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-362 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
0 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
500 | USD |
| CY2017Q3 | us-gaap |
Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
|
-5731 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
|
0 | USD |
| CY2017Q3 | antb |
Repayments Of Capital Lease Payable
RepaymentsOfCapitalLeasePayable
|
0 | USD |
| CY2016Q3 | antb |
Repayments Of Capital Lease Payable
RepaymentsOfCapitalLeasePayable
|
23128 | USD |
| CY2017Q3 | antb |
Fair Value Of Financial Instruments Earnings
FairValueOfFinancialInstrumentsEarnings
|
342 | USD |
| CY2017Q3 | us-gaap |
Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
|
246 | USD |
| CY2017Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2252739 | USD |
| CY2017Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1986127 | USD |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
11090000 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
135000 | shares |
| CY2017Q3 | us-gaap |
Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
|
25000 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
21400751 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
7815876 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.15 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
1 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.65 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
2.21 | |
| CY2017Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y6M | |
| CY2017Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y3M18D | |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year Gross
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYearGross
|
519829 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due In Two Years Gross
OperatingLeasesFutureMinimumPaymentsDueInTwoYearsGross
|
712360 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due In Three Years Gross
OperatingLeasesFutureMinimumPaymentsDueInThreeYearsGross
|
664696 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due In Four Years Gross
OperatingLeasesFutureMinimumPaymentsDueInFourYearsGross
|
338392 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due In Five Years Gross
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsGross
|
347836 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due Thereafter Gross
OperatingLeasesFutureMinimumPaymentsDueThereafterGross
|
569364 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Remainder Of Fiscal Year
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsRemainderOfFiscalYear
|
114435 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Two Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
|
157187 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Three Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
|
148551 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Four Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
|
0 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Five Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears
|
0 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Thereafter
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
|
0 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
405394 | USD |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
555173 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
516145 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
338392 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
347836 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
569364 | USD |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
53728640 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
53728640 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
49228640 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
49228640 | shares |
| CY2017Q3 | us-gaap |
Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
|
979766 | USD |
| CY2016Q3 | us-gaap |
Health Care Organization Medical Supplies And Drugs Expense
HealthCareOrganizationMedicalSuppliesAndDrugsExpense
|
0 | USD |
| CY2017Q3 | us-gaap |
License Costs
LicenseCosts
|
770900 | USD |
| CY2016Q3 | us-gaap |
License Costs
LicenseCosts
|
0 | USD |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4310637 | USD |
| CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2485929 | USD |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2406492 | USD |
| CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1337755 | USD |
| CY2017Q3 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2016Q3 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2017Q3 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2016Q3 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2017Q3 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
0 | USD |
| CY2016Q3 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
59028 | USD |
| CY2017Q3 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><u>Note 1 Nature of Operations</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), and its wholly owned operating subsidiary, AntriaBio Delaware, Inc. (“Antria Delaware”). AntriaBio and Antria Delaware are collectively referred to herein as the “Company”. The Company is a clinical stage biopharmaceutical Company.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q2 | us-gaap |
Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
|
588 | USD |
| CY2017Q3 | antb |
Working Capital Deficit
WorkingCapitalDeficit
|
2673071 | USD |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7317343 | USD |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7311528 | USD |
| CY2016Q3 | antb |
Investor Relations Expense
InvestorRelationsExpense
|
36225 | USD |
| CY2017 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
8100000 | USD |
| CY2017 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
186671 | USD |
| CY2017Q3 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
4440000 | USD |
| CY2017Q3 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
60000 | USD |
| CY2017Q3 | antb |
Operating Leases Future Minimum Payments Due Gross
OperatingLeasesFutureMinimumPaymentsDueGross
|
3152477 | USD |
| CY2017Q3 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions
FutureMinimumSubleaseRentalsSaleLeasebackTransactions
|
420173 | USD |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2732304 | USD |
| CY2014Q2 | us-gaap |
Area Of Land
AreaOfLand
|
27000 | acre |
| CY2014Q2 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
28939 | USD |
| CY2014Q2 | antb |
Payments Of Monthly Lease Adjusted Annually Percentage
PaymentsOfMonthlyLeaseAdjustedAnnuallyPercentage
|
0.03 | pure |
| CY2014Q2 | antb |
Adjusted Triple Net Expense Of Lease Payments
AdjustedTripleNetExpenseOfLeasePayments
|
34381 | USD |
| CY2014Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
750000 | USD |
| CY2014Q2 | us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
375000 | USD |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
32771448 | shares |
| CY2017Q3 | antb |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExpiredInPeriod
|
25000 | shares |
| CY2017Q3 | antb |
Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
|
1.65 | |
| CY2017Q3 | antb |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
|
1.71 | |
| CY2017 | antb |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerm
|
P3Y8M12D | |
| CY2017Q3 | antb |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerm
|
P3Y6M | |
| CY2017Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
10268075 | USD |
| CY2017Q3 | antb |
Fair Value Of Warrants
FairValueOfWarrants
|
246 | USD |
| CY2017 | antb |
Fair Value Of Warrants
FairValueOfWarrants
|
588 | USD |
| CY2017Q3 | antb |
Investor Relations Expense
InvestorRelationsExpense
|
0 | USD |
| CY2017Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1507699 | USD |
| CY2017Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4440000 | USD |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
21290751 | shares |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.65 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M12D | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
32796448 | shares |
| CY2017Q2 | antb |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
|
1.71 |
